Page 36 - CPG - Clinical Practice Guidelines - Management of Cancer Pain
P. 36

Management of Cancer Pain (Second Edition)
                  R[\FRGRQH ZLWKLQ RQH KRXU RI LQJHVWLRQ DQG DQ DQDOJHVLF GXUDWLRQ RI
                  hours. 36, level III

                  ‡   )HQWDQ\O
                  Fentanyl is an alternative opioid that can be used in cancer pain. In
                  Malaysia, it is available as transdermal patch, sublingual and parenteral
                  preparations.
                  Transdermal (TD) fentanyl should only be considered in patients with
                  VWDEOH RSLRLG UHTXLUHPHQWV ZKR KDYH GLI¿FXOW\ VZDOORZLQJ RU LQWUDFWDEOH
                                    9
                  nausea and vomiting.   In  a Cochrane systematic review comparing
                  TD fentanyl with oral morphine for relief of cancer pain, there was
                  LQVXI¿FLHQW  FRPSDUDEOH  GDWD  IRU  D  PHWD DQDO\VLV  WR  EH  XQGHUWDNHQ
                  for  the analgesic effect.  However,  transdermal fentanyl showed a
                  reduction in constipation (RR=0.61, 95% CI 0.47 to 0.78; NNT=5.5). No
                  meaningful analysis was possible for other AEs. 37, level I
                  When switching from other opioids to transdermal fentanyl, there is a
                  lag time between application of the patch and onset of analgesia due to
                  its pharmacokinetics whereby on average, minimally effective plasma
                  concentrations  of fentanyl  are seen  in 12 hours. Regular  4-hourly
                  oral opioids  should  therefore, be discontinued  12 hours after patch
                  DSSOLFDWLRQ  6LPLODUO\  ZKHQ FRQYHUWLQJ IURP 65 RSLRLG SUHSDUDWLRQV  WKH
                                                                          9
                  SDWFK VKRXOG EH DSSOLHG WRJHWKHU ZLWK WKH ODVW GRVH RI 65 PHGLFDWLRQ
                  However, an RCT on the conversion of IV to transdermal fentanyl in
                  chronic cancer pain revealed that the effectiveness of continuing the IV
                  IRU VL[ KRXUV DIWHU SDWFK DSSOLFDWLRQ    K PHWKRG  ZDV HTXLYDOHQW WR WKH
                  12-h method in terms of number of rescue doses for breakthrough pain
                  required (p>0.05) and thus may be considered for a simpler method of
                  conversion. 38, level I

                  7KH 7PD[ RI WUDQVGHUPDO IHQWDQ\O LV         KRXUV DQG WKH GXUDWLRQ RI
                  action is 72 hours. The plasma half-life of transdermal fentanyl ranges
                  IURP         KRXUV  3DUHQWHUDO IHQWDQ\O  H J  EROXVHV RI ,9 6&  KDV D
                  VKRUW GXUDWLRQ RI DFWLRQ RI DSSUR[LPDWHO\    PLQXWHV DQG LV QRW URXWLQHO\
                  used for maintenance therapy. 34
                  Fentanyl is generally considered a safer opioid in renal impairment as
                  its metabolites have minimal effect. 39, level I
                  7KH DSSUR[LPDWH SKDUPDFRNLQHWLF SDUDPHWHUV RI PRUSKLQH  R[\FRGRQH
                  and fentanyl are shown in Table 3.







                                             18




          e-cpg inside text-Cancer pain-25/5/24.indd   18               09/08/2024   12:09 AM
   31   32   33   34   35   36   37   38   39   40   41